120 related articles for article (PubMed ID: 8461645)
21. Carcinoembryonic antigen in patients with different cancers.
Reynoso G; Chu TM; Holyoke D; Cohen E; Nemoto T; Wang JJ; Chuang J; Guinan P; Murphy GP
JAMA; 1972 Apr; 220(3):361-5. PubMed ID: 4622794
[No Abstract] [Full Text] [Related]
22. Cytokeratin staining for primary and metastatic colorectal cancer.
Kummar S; Ciesielski TE
Clin Colorectal Cancer; 2001 Nov; 1(3):187-8. PubMed ID: 12450437
[TBL] [Abstract][Full Text] [Related]
23. Is immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas?
Cheung AN; Chiu PM; Khoo US
Hum Pathol; 1997 Jan; 28(1):91-4. PubMed ID: 9013838
[TBL] [Abstract][Full Text] [Related]
24. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
Dennis JL; Hvidsten TR; Wit EC; Komorowski J; Bell AK; Downie I; Mooney J; Verbeke C; Bellamy C; Keith WN; Oien KA
Clin Cancer Res; 2005 May; 11(10):3766-72. PubMed ID: 15897574
[TBL] [Abstract][Full Text] [Related]
25. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Brenner PC; Rettig WJ; Sanz-Moncasi MP; Reuter V; Aprikian A; Old LJ; Fair WR; Garin-Chesa P
J Urol; 1995 May; 153(5):1575-9. PubMed ID: 7536270
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.
Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ
J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521
[TBL] [Abstract][Full Text] [Related]
28. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells.
Matthew EM; Zhou L; Yang Z; Dicker DT; Holder SL; Lim B; Harouaka R; Zheng SY; Drabick JJ; Lamparella NE; Truica CI; El-Deiry WS
Oncotarget; 2016 Jan; 7(4):3662-76. PubMed ID: 26695546
[TBL] [Abstract][Full Text] [Related]
29. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor.
Gomez-Fernandez C; Mejias A; Walker G; Nadji M
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):137-41. PubMed ID: 19875957
[TBL] [Abstract][Full Text] [Related]
31. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case.
Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y
Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193
[TBL] [Abstract][Full Text] [Related]
32. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases.
Bates AW; Baithun SI
Histopathology; 2000 Jan; 36(1):32-40. PubMed ID: 10632749
[TBL] [Abstract][Full Text] [Related]
33. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.
Ramaekers F; van Niekerk C; Poels L; Schaafsma E; Huijsmans A; Robben H; Schaart G; Vooijs P
Am J Pathol; 1990 Mar; 136(3):641-55. PubMed ID: 1690512
[TBL] [Abstract][Full Text] [Related]
34. [On the immunologic sensitizability of tumor patients].
Hegemann F
Arch Geschwulstforsch; 1968; 32(4):339-52. PubMed ID: 4308112
[No Abstract] [Full Text] [Related]
35. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
36. Contribution of immunohistochemistry to the diagnosis of breast cancer in men.
Aziz DC; Milne C; Solomon S; Jothy SP
Can J Surg; 1986 Mar; 29(2):135-6. PubMed ID: 2420431
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
[TBL] [Abstract][Full Text] [Related]
38. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
39. Unknown primary tumours.
Hillen HF
Postgrad Med J; 2000 Nov; 76(901):690-3. PubMed ID: 11060142
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal anti-CEA antibodies in the discrimination between primary pulmonary adenocarcinoma and colon carcinoma metastatic to the lung.
Ghoneim AH; Brisson ML; Fuks A; Mobasher AA; Kreisman H
Mod Pathol; 1990 Sep; 3(5):613-8. PubMed ID: 2235987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
